2nd International Alloimmune
Conference on Hemolytic Disease of
Fetus and Newborn
Leiden, The Netherlands
The 2nd international alloimmune conference brings together
clinicians, laboratory professionals, scientists, patient organizations, policymakers, and innovators to share knowledge and shape the future of HDFN care and global health policy.
The alloimmune conference is organized by LUMC, Sanquin, WiRhE & AFRICARhE.
With support of ISBT
Program Overview
28 May, Leiden
Global anti-D
shortage
___________________
Although anti-D prophylaxis is highly effective, HDFN continues to result in avoidable mortality and long-term morbidity across the world.
This day is dedicated to exploring the global anti-D shortage and pathways toward sustainable, scalable solutions.
The program will address strategies to increase polyclonal anti-D supply, promote equitable access, and evaluate emerging monoclonal anti-D approaches.
29 May, Leiden
Worldwide variations on clinical
practice of HDFN
___________________
In recent years, multiple studies have demonstrated substantial variation in the management of HDFN.
This day will focus on understanding why such large international differences exist in HDFN screening, diagnosis, and management. The program includes keynote speakers, results from the pre-conference questionnaire, and panel discussions.
Participate in this conference
Advancing prevention, treatment, and equity in HDFN